Biotech Values

[acgood]

SNTA telegraphing that the ITT population PFS benefit won't be stat-sig at the interim

1. leading with fact that phase 3 will not be all comers
2. small number of events make such an outcome unlikely anyway
3. repeated emphasis of subgroups and zero commentary about results see in ITT
4. no statistical/significance phrase ever used in any of the commentary (subsets or otherwise)
5. I'm a skeptical curmudgeon